Form S-1
We note that you have submitted an application for confidential treatment relating to certain of your exhibits. Please be advised that comments to this application, if any, will be sent under separate cover and that any such comments must be resolved prior to your requesting effectiveness of your registration statement.
No reply letter found.
Please confirm that the graphics included in your registration statement are the only graphics you will use in your prospectus. If those are not the only graphics, please provide any additional graphics prior to their use for our review.
No reply letter found.
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.Rest of the question
Similarly, please supplementally provide us with any research reports about you that are published or distributed in reliance upon Section 2(a)(3) of the Securities Act of 1933 added by Section 105(a) of the Jumpstart Our Business Startups Act by any broker or dealer that is participating or will participate in your offering.
No reply letter found.
Please define the terms “hydrogel” and “intravitreal” in this section.
No reply letter found.
Please note here that your entire intellectual property portfolio and much of the technology you utilize is licensed from Incept, LLC, a related party.
No reply letter found.
Please state the approximate amount of time it takes for your punctum plugs to dissipate after their active pharmaceutical ingredients have been exhausted.
No reply letter found.
Please briefly discuss the therapeutic effects of both dexamethasone and travoprost.
No reply letter found.
In your summary discussion of ReSure Sealant please disclose that you had previously initiated and then discontinued commercialization of an earlier version of this product in Europe and that the FDA also requested withdrawal of your initial application for that version.
No reply letter found.
Please include a bullet point summarizing the material risk discussed in the risk factor on pages 37-38 and cite the FDA’s condition requiring post-approval studies for ReSure Sealant as an example. Risk Factors Risks Related to Our Financial Position and Need for Additional Capital “Our substantial indebtedness may limit cash flow available to invest in the ongoing needs of our business,” page 15
No reply letter found.
Please provide examples of the types of corporate actions the restrictive covenants included in your credit agreement may prevent you from undertaking. Risks Related to Our Product Development “If clinical trials of our punctum plug product candidates or any other product candidate that we develop . . .,” page 17
No reply letter found.
Here, and wherever else applicable in your registration statement, please state the reason(s) to your knowledge that the FDA requested you withdraw your application for ReSure Sealant submitted under Section 510(k) of the FDCA. “If serious adverse or unacceptable side effects are identified during the development of our punctum plug product candidates . . .,” page 20
No reply letter found.
Please amend this risk factor to provide examples of the adverse events that have been identified in your clinical trials. Risks Related to Manufacturing “If our sole clinical manufacturing facility is damaged or destroyed or production at this facility is otherwise interrupted . . .,” page 22
No reply letter found.
Please amend this risk factor to include the limit of your insurance coverage.
No reply letter found.
Here, on page 60 of your disclosure, and wherever else applicable in your registration statement, please cite the total revenue generated by ReSale Sealant during the period of commercialization in Europe.
No reply letter found.
Please remove the last sentence of this section. Asserting that you have not independently verified information included in your registration statement can be construed as disclaiming responsibility for such information, which is not appropriate.
No reply letter found.
Please include separate bullet points identifying the amount of net proceeds you intend to allocate toward expanding your manufacturing capacity and the amount to be allocated on sales and marketing activities, and remove the references to them from your last bullet point.
No reply letter found.
Similarly, please include a separate bullet point that identifies the amount of net proceeds you intend to allocate toward preclinical product development and remove the reference to this from your last bullet point.
No reply letter found.
Please include a separate bullet point that discloses the amount of net proceeds, if any, you intend to allocate toward payment of the loans you have borrowed under your credit facility.
No reply letter found.
Please tell us the factors contributing to the increase in the common stock fair value of $0.94 on September 12, 2013 to $1.45 on November 7, 2013 to $3.33 on February 12, 2014. In addition, to the extent your estimated IPO price is significantly different from your most recent valuation at March 27, 2014, please tell us the factors contributing to the change in the common stock fair value.Rest of the question
Please note that we will defer our evaluation of any stock compensation issues until an estimated IPO price has been determined.
No reply letter found.
Please provide us a table and narratives that disclose all equity issuances to date or confirm that no additional equity issuances such as options, warrants, preferred stock, common stock, etc. were made subsequent to April 14, 2014.
No reply letter found.
In your discussion of clinical trials, please explain more clearly what the p-values and nvalues cited represent, where applicable.
No reply letter found.
Where you reference the three severe adverse events experienced by participants in the Phase 2 trial on page 97, please provide the basis for your assertion that they were unrelated to the study treatment.
No reply letter found.
In your discussion of the pilot studies and clinical study please state the reason(s) to your knowledge why certain of the plugs would not be retained over the entire study period.
No reply letter found.
In your description of the clinical trial, please further explain your statement that 0% of the plugs being present at the end of the trial indicated that it functioned as designed.
No reply letter found.
In your discussion of the pivotal clinical trial, please specify which p-value represents statistical significance.
No reply letter found.
Please indicate the number of Investigational New Drug Application(s) you have filed with the FDA to date, the product candidate(s) and indication(s) to which they relate and the approximate date(s) when filed.
No reply letter found.
Please file a copy of the form lock-up agreement as an exhibit to your registration statement or, alternatively, please confirm that it will be filed as an exhibit to your underwriting agreement. Financial Statements Notes to Financial Statements 2. Summary of Significant Accounting Policies
No reply letter found.
Please tell us why you did not reflect the April 2014 financing in the pro forma here as you have in other parts of the filing.
No reply letter found.
Please disclose how much inventories were expensed during the periods presented in preparation for the launch of ReSure Sealant during the first quarter of 2014. If you intend to respond to these comments with an amended draft registration statement, please submit it and any associated correspondence in accordance with the guidance we provide in the Division’s October 11, 2012 announcement on the SEC website atRest of the question
http://www.sec.gov/divisions/corpfin/cfannouncements/drsfilingprocedures101512.htm. Please keep in mind that we may publicly post filing review correspondence in accordance with our December 1, 2011 policy (http://www.sec.gov/divisions/corpfin/cfannouncements/edgarcorrespondence.htm). If you intend to use Rule 83 (17 CFR 200.83) to request confidential treatment of information in the correspondence you submit on EDGAR, please properly mark that information in each of your confidential submissions to us so we do not repeat or refer to that information in our comment letters to you.
No reply letter found.
We note your response to prior comment 11. Please explain why, to your knowledge, the FDA did not believe the technical characteristics of your earlier version of ReSure Sealant were substantially equivalent to a predicate device and also explain the significance of this determination.
No reply letter found.
We note your response to prior comment 22. Please describe the factors that led your trial investigator to conclude that none of the serious adverse events identified were related to the study treatment. If you intend to respond to these comments with an amended draft registration statement, please submit it and any associated correspondence in accordance with the guidance we provide in the Division’s October 11,Rest of the question
2012 announcement on the SEC website at http://www.sec.gov/divisions/corpfin/cfannouncements/drsfilingprocedures101512.htm.
No reply letter found.